Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Comcast Corporation (CMCSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Comcast Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Comcast Corporation trades at $23.61 (market cap $84.20B). The key difference: Comcast Corporation is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Comcast Corporation pays a 5.6% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CMCSA | |
|---|---|---|
Market Cap | $39.89B | $84.20B |
Sector | Health | Media |
52-Week High | $491.22 | $33.81 |
52-Week Low | $278.09 | $22.32 |
Enterprise Value | $38.15B | $169.34B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CMCSA trades at $23.57, up 0.96% with strong fundamentals including a low P/E of 4.62 and net income margin of 15%. Recent earnings beats and a $2.14B acquisition of ITV's media unit signal strategic growth. Technicals are bearish with support at $23, while analyst consensus remains bullish with a $30.94 price target.
Outlook: Undervalued with robust cash flow and dividend yield, but weighed by bearish technicals and spin-off uncertainty. Key risks include integration challenges from acquisitions and competitive pressures in media and broadband sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
